ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

isatuximab

Also written as “Isatuximab SAR650984”, “Isatuximab” and “isatuximab SAR650984”.

Its studies are mostly in Multiple Myeloma · Lymphoma · Immune System Diseases · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Anemia, Hemolytic, Autoimmune, led by 3 companies.

Drug pageIsatuximab: every studyAll 73 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 4, 201623 company-led studies, 6 open or runningNext primary completion: Apr 5, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only215 open or runningphase 3since Dec 4, 2016Mar 9, 2010Apr 5, 2027phase 3 · NCT03319667
GlaxoSmithKlineits history only11 open or runningphase 2since Oct 13, 2025Oct 13, 2025none ahead
Hoffmann-La Roche10 open or runningphase 2since May 31, 2018May 31, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 31, 2018First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT03555149 · 96 enrolled · United States, Australia, France and more

TargetBeta

CD38 →read by rule
“A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03555149Colorectal Neoplasms · United States, Australia, France and more2TerminatedSep 26, 202296

How it is read

Names in the registry

  • “Isatuximab SAR650984”, 11 entries
  • “Isatuximab”, 6 entries
  • “isatuximab SAR650984”, 3 entries
  • “Isatuximab intravenous (IV)”, 1 entry
  • “Isatuximab subcutaneous (SC)”, 1 entry

Codes read as this program: SAR650984.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.